Le Sun Pharmaceuticals

Le Sun Pharmaceuticals is a biopharmaceutical company based in Changzhou, China, that focuses on the discovery and development of next-generation small molecule anti-cancer therapeutics. Founded in 2011 and operating as a key innovation subsidiary of Changzhou Qianhong Biopharma, the company specializes in targeting cell cycle regulators such as cyclin-dependent kinases (CDKs). Its lead clinical asset, Sunaciclib (QHRD107), is a potent CDK9 inhibitor currently in Phase 2 clinical trials for acute myelocytic leukemia and solid tumors. Beyond its internal drug pipeline, Le Sun Pharmaceuticals provides a wide range of CDMO and CRO services, including API process development, formulation research, and analytical testing support. The company maintains significant academic and industry partnerships, including a joint laboratory with the University of South Australia and a strategic collaboration with Yabao Pharmaceutical Group.